To include your compound in the COVID-19 Resource Center, submit it here.

BMS, AZN report dapagliflozin cancer rates

Bristol-Myers Squibb Co. (NYSE:BMY) and partner AstraZeneca plc (LSE:AZN; NYSE:AZN) reported an imbalance in two tumor types in the dapagliflozin clinical

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE